Molecular docking study of A3 adenosine receptor antagonists and pharmacophore-based drug design

Adenosine is known to act as a neuromodulator by suppressing synaptic transmission in the central and peripheral nervous system. A(3) adenosine receptor (A(3)AR) antagonists were recently considered as potential drugs for the treatment of cardiac ischemia and inflammation diseases. To better understand the chemical features responsible for the recognition mechanism and the receptor-ligand interaction, we have performed the molecular simulation study combined with a virtual library screening process to develop novel A(3)AR antagonists. A series of A(3)AR selective antagonists, including triazolopurines, imidazopurines, pyrrolopurines, and quinazolines were employed to dock into the A(3)AR binding site via AUTODOCK software. The putative binding mode for each compound was proposed. Three main hydrophobic pockets, one hydrogen bonding with Asn250, and one pi-pi interaction with Phe168 for all antagonists were identified. The most favorable binding conformations served as the templates for pharmacophore modeling with Catalyst 4.11 and a virtually generated library have been screened for novel antagonist development.

[1]  C. Müller,et al.  Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. , 2006, Current topics in medicinal chemistry.

[2]  Jing Wei,et al.  3D-Pharmacophore Models for Selective A2A and A2B Adenosine Receptor Antagonists , 2007, J. Chem. Inf. Model..

[3]  Kenneth A. Jacobson,et al.  Structural Determinants of A3 Adenosine Receptor Activation: Nucleoside Ligands at the Agonist/Antagonist Boundary , 2002 .

[4]  K. Jacobson,et al.  A physiological role of the adenosine A3 receptor: sustained cardioprotection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Stone,et al.  A3 adenosine receptors regulate Cl-channels of nonpigmented ciliary epithelial cells. , 1999, American journal of physiology. Cell physiology.

[6]  P. Borea,et al.  Adenosine A3 receptor , 2001 .

[7]  K. Varani,et al.  Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine ligands, new tools to characterize A3 adenosine receptors in human tumor cell lines. , 2005, Current medicinal chemistry.

[8]  Y. Kurogi,et al.  1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands. , 2002, Journal of medicinal chemistry.

[9]  Qingzhi Gao,et al.  Computational studies of the binding modes of A2A adenosine receptor antagonists , 2007, Amino Acids.

[10]  P. Fishman,et al.  Pharmacology and therapeutic applications of A3 receptor subtype. , 2003, Current topics in medicinal chemistry.

[11]  A. IJzerman,et al.  Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. , 2000, Journal of medicinal chemistry.

[12]  K. Varani,et al.  New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists. , 2005, Journal of medicinal chemistry.

[13]  C. Caux,et al.  Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. , 2003, Molecular pharmacology.

[14]  K. Jacobson,et al.  Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor* , 2002, The Journal of Biological Chemistry.

[15]  J. Shimada,et al.  KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. , 2002, European journal of pharmacology.

[16]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[17]  K. Jacobson,et al.  Adenosine A3 receptors: novel ligands and paradoxical effects. , 1998, Trends in pharmacological sciences.

[18]  Giampiero Spalluto,et al.  Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. , 2005, Trends in pharmacological sciences.

[19]  A. Bianucci,et al.  2,9-disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: synthesis, biochemical and molecular modelling studies. , 2005, Bioorganic & medicinal chemistry.

[20]  C. Franceschi,et al.  Activation of the A3 adenosine receptor affects cell cycle progression and cell growth , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[21]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..